Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Provectus Biopharmaceuticals Inc PVCT

Healthcare
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform... see more

Recent & Breaking News (OTCQB:PVCT)

PV-10 Data Presented by Moffitt Cancer Center Researchers Examines Induction of Systemic Immune Response in Multiple Tumor Types

Business Wire April 10, 2013

Provectus Presents Data on PV-10 Combination Therapy at American Association of Cancer Research Annual Meeting

Business Wire April 10, 2013

PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the American Association for Cancer Research Annual Meeting

Business Wire April 8, 2013

BUYINS.NET Issues Provectus Pharmaceuticals SqueezeTrigger Report

Globe Newswire April 1, 2013

Immunology Data on PV-10 to Be Presented at the American Association for Cancer Research Annual Meeting

Business Wire March 21, 2013

Data on Provectus's PV-10 to Be Presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on March 22, 2013

Business Wire March 20, 2013

Provectus Pharmaceuticals Shares Are Trading on the OTCQB

Business Wire January 25, 2013

Provectus Pharmaceuticals Launches Free Mobile Investor Relations Application

Business Wire January 24, 2013

Provectus Pharmaceuticals Announces H. Lee Moffitt Cancer Center Initiates Phase 1 Study of PV-10 to Elucidate Bystander Effect

Business Wire January 8, 2013